期刊文献+

门诊患者倍他乐克不规范用药分析 被引量:2

Analysis of Incorrect Usage of Betaloc in Outpatients
原文传递
导出
摘要 目的:针对门诊患者使用倍他乐克不规范的原因进行分析,为临床规范用药提供参考。方法:搜集2011年7月本院心内科普通门诊服用倍他乐克的患者病例,分析其中用药不当的原因以及各种具体表现。结果:373例使用倍他乐克的患者中,不规范用药者占9.39%,包括了用量、用法不正确、擅自减量、停药以及拒绝用药等12种用药不当的具体表现。在不规范用药的患者中,有9人随访间隔时间明显短于其余患者(P<0.05),但未被告知调整药物剂量。有8位患者年龄显著高于其余患者(P<0.05),由于独居或行动不便,随访间隔时间明显长于其余患者(P<0.05)。结论:倍他乐克使用不规范的情况并不少见,应当加强临床医师的教育以及对患者的宣教,增加用药的依从性,提高倍他乐克用药的规范性与合理性。 Objective: To investigate the incorrect usage of Betaloc in outpatients, in order to provide the instructions for usage of Betaloc. Methods: A total of 373 outpatients, who were outpatients in department of cardiology, Affiliated DrumTower Hospital, Nanjing University in July 2011, were collected. The causes and details of incorrect usage of Betaloc were summarized. Results: Of the 373 patients using Betaloc, 9.39% patients took the drug incorrectly. 12 manifestations were listed, including incorrect dosage and frequency, decrease or discontinuation of the drug without doctor's advice and refusal to the drug. Among the patients of incorrect drug use, 9 patients were followed up more closely than the others (P〈0.05), but they were not told to adjust the dosage of Betaloc; 8 patients were much older than the others significantly (P〈0.05) and they visited the clinic least (P〈0.05) for sake of inconvenience action or helplessness. Conclusions: It is common that Betaloc is incorrectly used in clinic. Thus, it is necessary to strengthen the education and publicity, and to improve normative rationality in the usage of Betaloc.
出处 《现代生物医学进展》 CAS 2013年第2期288-291,共4页 Progress in Modern Biomedicine
关键词 PER1 LAMR1 门诊 倍他乐克 不规范 PER1 LAMR1 Outpatient Betaloc Incorrect
  • 相关文献

参考文献15

  • 1Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker- induced heart rate lowering and cardioprotection in hypertension[J]. J Am Coil Cardiol, 2008, 52(18): 1482-1489.
  • 2Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy [J]. J Clin Hypertens (Greenwich), 2005, 7(7): 409-416.
  • 3Hjalmarson A. Prevention of sudden cardiac death with beta blockers [J]. Clin Cardiol, 1999, 22, Suppl 5:V11-15.
  • 4Castagno D, Jhund PS, McMurray J J, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolo 1 study II (CIBIS-II) trial[J]. Eur J Heart Fail, 2010, 12(6): 607-616.
  • 5Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial [J]. Clin Cardiol, 1999, 22, Suppl5:V30-35.
  • 6Shivkumar K, Schultz L, Goldstein S, et al. Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression[J]. Am Heart J, 1998, 135:261-267.
  • 7Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)[J]. Circulation, 2004, 110(9): e282-292.
  • 8Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [J]. Circulation, 2009, 119(14): 1977-2016.
  • 9刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-708. 被引量:6936
  • 10张海波,张丹,李静,李希,冯芳,刘佳敏,高岩,乌汉毕力格,葛蕾,庞鑫,CHEN Yiping,CHEN Zhengming,LANDRAY Martin,ARMITAGEJane,CHEN Fang,蒋立新.β受体阻滞剂在中国高危冠心病患者中的应用现状调查[J].临床心血管病杂志,2011,27(6):422-425. 被引量:25

二级参考文献79

共引文献7256

同被引文献14

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部